Verastem (NASDAQ: VSTM) reported Q2 EPS of ($0.23), $0.06 better than the analyst estimate of ($0.29).

Financial Guidance

Based on current operating plans, we expect to have sufficient cash, cash equivalents and short-term investments to fund our research and development programs and operations into 2018.

For earnings history and earnings-related data on Verastem (VSTM) click here.